← Dashboard
Stock
RCKT
Rocket Pharmaceuticals, Inc.Latest close $3.079 of 27 marquee funds currently hold4 CUSIPs mapped
Current holders
9
27 funds tracked
Ever held
12
Current + past
New this quarter
1
Exited this quarter
3
Marquee-fund ownership over time
May 14, 2021Nov 13, 2024Aug 14, 2025May 15, 2026
Now
16
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Maverick Capital re-entered | Q2 2021 | 21Q | $40 | $3.07 | -92% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $19 | $3.07 | -84% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $3.07 | -83% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $3.07 | -83% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $3.07 | -83% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $3.07 | -83% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $18 | $3.07 | -83% |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $15 | $3.07 | -79% |
| Soros Fund Management re-entered | Q2 2025(8Q snapshot) | 4Q | $13 | $3.07 | -76% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Bridgewater Associates | Q1 2026 | Q2 2026 | → $13 | -29% |
| Third Point 2× in & out | Q3 2025 | Q2 2026 | → $13 | -29% |
| Coatue Management | Q1 2026 | Q2 2026 | → $13 | -27% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ROCKET PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
9
Filings · last 90d
9
Total on file
333
Recent SEC buffer
Most recent
May 28, 2026
30d / 90d windows measured from May 28, 2026 — the most recent Form 4 on file — not from today.
- Form 40001140361-26-023153May 28, 2026
- Form 40001140361-26-022894May 26, 2026
- Form 40001140361-26-022447May 21, 2026
- Form 40001140361-26-022446May 21, 2026
- Form 40001140361-26-022445May 21, 2026
- Form 40001140361-26-021321May 14, 2026
- Form 40001140361-26-021315May 14, 2026
- Form 40001140361-26-021305May 14, 2026
- Form 40001140361-26-020649May 11, 2026
- Form 40001140361-26-006330Feb 20, 2026
- Form 40001140361-26-006326Feb 20, 2026
- Form 40001140361-26-006317Feb 20, 2026
- Form 40001140361-26-006047Feb 18, 2026
- Form 40001140361-26-006045Feb 18, 2026
- Form 40001140361-26-006043Feb 18, 2026
Showing 15 of 333 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Rocket Pharmaceuticals, Inc.Annual figures sourced directly from Rocket Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$0
FY2025
Net income
-$223.12M
FY2025+14% YoY
EPS (diluted)
$-2.01
FY2025+26% YoY
Free cash flow(?)
-$190.45M
FY2025+12% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ROCKET PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 21, 2026
- 8-KMaterial eventMay 7, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventApr 28, 2026
- DEF 14AProxy statementApr 6, 2026
- 8-KMaterial eventMar 27, 2026
- 8-KMaterial eventMar 10, 2026
- S-3Registration (shelf)Mar 2, 2026
- 8-KMaterial eventFeb 26, 2026
- 10-KAnnual reportFeb 26, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventOct 14, 2025
- 8-KMaterial eventOct 3, 2025
- 8-KMaterial eventOct 3, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $14 | $13 | -9% |
| Coatue Management | Q1 2026 | Q2 2026 | $18 | $13 | -27% |
| Point72 Asset Management | Q1 2026 | open | $3.31 | $3.07 | -7% |
| Bridgewater Associates | Q1 2026 | Q2 2026 | $19 | $13 | -29% |
| Soros Fund Management | Q1 2026 | open | $19 | $13 | -30% |
| Two Sigma Investments | Q3 2025 | open | $3.03 | $3.07 | +1% |
| Third Point | Q3 2025 | Q2 2026 | $19 | $13 | -29% |
| D.E. Shaw | Q3 2025 | open | $3.03 | $3.07 | +1% |
| Point72 Asset Management | Q3 2025 | open | $19 | $13 | -30% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | $20 | $18 | -10% |
| Soros Fund Management | Q2 2025 | Q4 2025 | $13 | $17 | +34% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $12 | $13 | +3% |
| Renaissance Technologies | Q1 2025 | open | $10 | $3.07 | -70% |
| AQR Capital Management | Q4 2024 | open | $15 | $3.07 | -79% |
| Point72 Asset Management | Q4 2024 | Q2 2025 | $15 | $6.72 | -55% |
| Citadel Advisors | Q3 2024 | Q2 2026 | $18 | $3.25 | -82% |
| Citadel Advisors | Q3 2024 | open | $18 | $13 | -28% |
| Citadel Advisors | Q3 2024 | open | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $18 | $6.72 | -63% |
| Two Sigma Investments | Q3 2024 | open | $18 | $13 | -28% |
| D.E. Shaw | Q3 2024 | open | $18 | $13 | -28% |
| AQR Capital Management | Q3 2024 | open | $18 | $13 | -28% |
| Millennium Management | Q3 2024 | open | $18 | $13 | -28% |
| Millennium Management | Q3 2024 | open | $18 | $3.07 | -83% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $19 | $16 | -18% |
| Renaissance Technologies | Q3 2024 | Q2 2025 | $17 | $13 | -26% |
| Maverick Capital | Q3 2021 | open | $30 | $2.89 | -90% |
| Maverick Capital | Q2 2021 | Q2 2023 | $40 | $22 | -46% |
| Third Point | Q2 2021 | Q3 2021 | $15 | $16 | +5% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.